Merck (NYSE: MRK), known as MSD in markets outside the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), have announced the launch of INTerpath-009, a pivotal Phase 3 randomized…
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central…
Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura) announced today its decision to withdraw the marketing authorization application for avacincaptad pegol intravitreal solution (ACP) from the European Medicines…
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940…
Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer,…
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed…
Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide…
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein…
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA…
Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G)…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the withdrawal of its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution…